Literature DB >> 28472619

Toll like receptor 4 and hepatocellular carcinoma; A systematic review.

Zahra Sepehri1, Zohre Kiani2, Farhad Kohan3, Seyed Moayed Alavian4, Saeid Ghavami5.   

Abstract

INTRODUCTION: Toll like receptor 4 (TLR4) is an extracellular pathogen recognition receptor (PRR) which recognizes a wide range of pathogens and damage associated molecular patterns (PAMPs and DAMPs). It can activate intracellular signaling and consequently transcription factors which participate in transcription from either immune related or malignancy genes. Thus, it has been hypothesized that TLR4 may be a cause of hepatocellular carcinoma (HCC). This article has reviewed the roles of TLR4 in the pathogenesis of HCC.
METHOD: "TLR4", "hepatocellular carcinoma", "liver tumor" and "liver cancer" were used as key words for searching in Scopus, Google Scholar and MEDLINE scientific databases.
RESULTS: Most of the investigations documented the roles of TLR4 in induction of HCC via several mechanisms including increased number of T regulatory lymphocytes and liver resident follicular helper like cells, increased production of pro-inflammatory and malignancy related molecules including cytokines, NANOG, Caspase-1, Ephrin-A1, NO and BCL6. TLR4 participates in the proliferation of the cells and also production of the molecules in both chronic infectious and non-infectious inflammatory diseases. DISCUSSION: TLR4 is an innate immunity receptor which plays a pathogenic role during chronic inflammation and can induce HCC in human.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hepatocellular carcinoma; Inflammation; TLR4

Mesh:

Substances:

Year:  2017        PMID: 28472619     DOI: 10.1016/j.lfs.2017.04.025

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  15 in total

1.  Photobiomodulation Therapy Improves Acute Inflammatory Response in Mice: the Role of Cannabinoid Receptors/ATP-Sensitive K+ Channel/p38-MAPK Signalling Pathway.

Authors:  Laís M S Neves; Elaine C D Gonçalves; Juliana Cavalli; Graziela Vieira; Larissa R Laurindo; Róli R Simões; Igor S Coelho; Adair R S Santos; Alexandre M Marcolino; Maíra Cola; Rafael C Dutra
Journal:  Mol Neurobiol       Date:  2017-10-04       Impact factor: 5.590

Review 2.  Hepatocellular Cancer and Gut Microbiome: Time to Untie Gordian's Knot.

Authors:  Cem Aygün; Nurdan Tözün
Journal:  J Gastrointest Cancer       Date:  2021-11-08

Review 3.  Danger signals in liver injury and restoration of homeostasis.

Authors:  Hui Han; Romain Desert; Sukanta Das; Zhuolun Song; Dipti Athavale; Xiaodong Ge; Natalia Nieto
Journal:  J Hepatol       Date:  2020-05-01       Impact factor: 25.083

Review 4.  Harnessing the Power of Eph/ephrin Biosemiotics for Theranostic Applications.

Authors:  Robert M Hughes; Jitka A I Virag
Journal:  Pharmaceuticals (Basel)       Date:  2020-06-01

5.  Up-regulation of RIP1 and IPS-1 in chronic HBV infected patients.

Authors:  Minoo Safari-Arababadi; Mohammad Hossein Modarressi; Mohammad Kazemi Arababadi
Journal:  Genet Mol Biol       Date:  2019-08-19       Impact factor: 1.771

6.  Bioinformatics Analysis Identifies Protein Tyrosine Kinase 7 (PTK7) as a Potential Prognostic and Therapeutic Biomarker in Stages I to IV Hepatocellular Carcinoma.

Authors:  Ren-Chao Zou; Yun Liang; Ling-Lin Li; Jian-Zhong Tang; Yan-Ping Yang; Yan-Chun Geng; Jie He; Li-Yun Luo; Wen-Xing Li; Zhi-Wei Sun; Hong-Ling Yuan
Journal:  Med Sci Monit       Date:  2019-11-15

Review 7.  Effects of therapeutic probiotics on modulation of microRNAs.

Authors:  Amirhossein Davoodvandi; Havva Marzban; Pouya Goleij; Amirhossein Sahebkar; Korosh Morshedi; Samaneh Rezaei; Maryam Mahjoubin-Tehran; Hossein Tarrahimofrad; Michael R Hamblin; Hamed Mirzaei
Journal:  Cell Commun Signal       Date:  2021-01-11       Impact factor: 5.712

Review 8.  The Potential Gut Microbiota-Mediated Treatment Options for Liver Cancer.

Authors:  Chunye Zhang; Ming Yang; Aaron C Ericsson
Journal:  Front Oncol       Date:  2020-10-14       Impact factor: 6.244

9.  Sorafenib inhibits caspase-1 expression through suppressing TLR4/stat3/SUMO1 pathway in hepatocellular carcinoma.

Authors:  Jun Li; Yuan Zhou; Yang Liu; Bo Dai; Yu-Hen Zhang; Peng-Fei Zhang; Xiao-Lei Shi
Journal:  Cancer Biol Ther       Date:  2018-10-02       Impact factor: 4.742

Review 10.  Molecular and Cellular Mechanisms Influenced by Postbiotics.

Authors:  Rafał Jastrząb; Damian Graczyk; Pawel Siedlecki
Journal:  Int J Mol Sci       Date:  2021-12-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.